Latest news with #SouthamptonClinicalTrialsUnit
Yahoo
31-07-2025
- Health
- Yahoo
Cancer blood test trial gives fresh hope to patients and families
A cancer blood test trial is giving fresh hope to patients and families. The MODERNISED study, currently running in Dorset, has recruited more than 450 participants as it evaluates a new blood test designed to detect multiple cancers at their earliest stages. Unlike other tests in development, the technology being trialled identifies immune system responses to cancer rather than relying on DNA markers. The test is also being assessed for its ability to pinpoint the type of cancer detected. The study is taking place at five hospitals across the UK, including University Hospitals Dorset and Dorset County Hospital. It is led by researchers in Southampton in collaboration with the Southampton Clinical Trials Unit and Proteotype Diagnostics Ltd. The trial is funded by the National Institute for Health and Care Research (NIHR) Invention for Innovation programme and the Office for Life Sciences. READ: Breakthrough blood test trial for dementia diagnosis begins in Dorset Ian Robinson taking part in MODERNISED at UHS. Ian Robinson, 72, who was diagnosed with colorectal cancer following routine screening, is among those taking part in the study. Mr Robinson said: "I was sent the NHS bowel cancer screening kit. "I think I had done four of these, normally with a negative result, but the most recent one indicated that there was a chance of cancer which was confirmed with a colonoscopy. "There were no symptoms, no pain, nothing, so you would never know until it was much more advanced and therefore much more difficult to treat." He said he was pleased to take part in the trial. Mr Robinson said: "Obviously the team here is helping me, so I'm delighted to participate and hopefully help improve the way things are done. "My mother died from cancer. I now have children and five grandchildren, so yes, research is absolutely vital. "The more cancers that can be identified as early as possible, that can benefit future generations, then it's obviously the right way to go." READ: Dorset charity helps woman to fund potentially life-extending cancer drug Victoria Goss, associate professor and head of Early Diagnosis Research at the Southampton Clinical Trials Unit. (Image: UHS) Each year, around 385,000 people in the UK are diagnosed with cancer. Dr Victoria Goss, associate professor and head of early diagnosis research at the Southampton Clinical Trials Unit, said: "When cancers are diagnosed later, there are often fewer treatment options available to patients. "Detecting cancer early means that treatment can begin sooner, increasing the chances of successful outcomes for patients. "Improving early diagnosis is therefore a priority for us as researchers and for the NHS. "But currently there are only four screening programmes in the UK and screening is only for one cancer at a time, so we are aiming to develop simple tests that can potentially pick up the signs of multiple cancers, giving the best possible chance of early, successful treatment." READ: Walkers raise over £900k for Macmillan Cancer Support Prof Andy Davies. (Image: UHS) The study is led by Professor Andy Davies, director of the Southampton Cancer Research UK and NIHR Experimental Cancer Medicine Centre. Professor Davies said: "Most current research into multi-cancer blood tests is focussed on detecting abnormal DNA that has been released into the blood stream by cancer cells. "But this circulating tumour DNA cannot always be detected in the very early stages of cancer. "We are instead looking at levels of certain proteins found in blood. "We know that even in the earliest stages of cancer, the body's immune response can lead to higher levels of these proteins being released, and we believe these may be a good way to test for early signs of the disease."
The Independent
31-07-2025
- Health
- The Independent
Unique blood test could catch cancer early
A new clinical trial, Enlighten, is assessing a blood test designed to detect 10 different types of cancer in their very early stages. Developed by Proteotype Diagnostics and led by the Southampton Clinical Trials Unit, the test identifies specific proteins in the blood that indicate the immune system's response to initial cancer signs. Unlike other tests focusing on abnormal DNA, Enlighten targets protein levels, which experts believe are more effective for detecting cancer at its earliest stages. The Modernised trial aims to recruit 1,000 patients across various solid tumour types, with 450 already participating, and is running at multiple hospital sites in the UK. Researchers emphasise that early cancer detection, facilitated by such tests, is crucial for improving treatment options and increasing successful outcomes for patients.
BBC News
31-07-2025
- Health
- BBC News
Patients trial blood test for detecting early-stage cancers
Hundreds of patients in Hampshire and Dorset are taking part in a trial for a blood test aimed at detecting early stage Enlighten test looks for certain proteins that indicate the immune system is responding to the first signs of the is also being evaluated to see if it can identify the type of cancer by the Southampton Clinical Trials Unit, the Modernised study aims to recruit 1,000 patients across the two counties, with 450 already signed up. Ian Robinson, a 72 year-old grandfather from Fawley, agreed to take part in the Southampton trial after an NHS bowel cancer screening kit led to a diagnosis of colorectal said: "There were no symptoms, no pain, nothing, so you would never know until it was much more advanced and therefore much more difficult to treat."Obviously the team here is helping me, so I'm delighted to participate and hopefully help improve the way things are done." Researchers will take blood samples from people with 10 solid tumour types, including bladder, breast, lung, prostate, ovarian, pancreatic, oesophageal and will also include patients with colorectal tumours and melanoma, a type of skin Victoria Goss, Associate Professor and Head of Early Diagnosis Research at the Southampton Clinical Trials Unit, said: "When cancers are diagnosed later, there are often fewer treatment options available to patients. "Improving early diagnosis is therefore a priority for us as researchers and for the NHS. "But currently there are only four screening programmes in the UK and screening is only for one cancer at a time, so we are aiming to develop simple tests that can potentially pick up the signs of multiple cancers, giving the best possible chance of early, successful treatment."Southampton Clinical Trials Unit is working with biotech company Prototype Diagnostics with patients from hospitals in Portsmouth, Southampton, Bournemouth, Poole and trial, which is also due to open in Manchester, is funded by the National Institute for Health and Care Research Invention for Innovation programme and the Office for Life Sciences. You can follow BBC Dorset on Facebook, X (Twitter), or Instagram.
Irish Independent
31-07-2025
- Health
- Irish Independent
Single blood test may be able to detect 10 types of cancer in their early stages
The test, which is known as Enlighten and developed by Proteotype Diagnostics, looks for certain proteins in the blood that indicate that the immune system is responding to the first signs of the disease. The trial will also assess if the test can identify which type of cancer a patient has. The trial, led by the Southampton Clinical Trials Unit (SCTU), is aiming to recruit 1,000 patients, with 450 already taking part. Experts will take samples from people with 10 solid-tumour types, including bladder, breast, lung, prostate, ovarian, pancreatic, oesophageal and renal. It will also include patients with colorectal tumours and melanoma, a type of skin cancer. Andy Davies, centre lead at Southampton's Experimental Cancer Medicine Centre, said: 'Most current research into multi-cancer blood tests is focused on detecting abnormal DNA that has been released into the blood stream by cancer cells. 'But this circulating tumour DNA cannot always be detected in the very early stages of cancer. 'We are instead looking at levels of certain proteins found in blood. 'We know that, even in the earliest stages of cancer, the body's immune response can lead to higher levels of these proteins being released, and we believe these may be a good way to test for early signs of the disease.' Victoria Goss, associate professor and head of early diagnosis research at SCTU, said: 'When cancers are diagnosed later, there are often fewer treatment options available to patients. 'Detecting cancer early means that treatment can begin sooner, increasing the chances of successful outcomes for patients. 'Improving early diagnosis is therefore a priority for us as researchers.' Emma Yates, co-founder and chief scientific officer of Proteotype Diagnostics, said preliminary studies show Enlighten 'has high levels of accuracy for picking up cancer in its very early stages'. She added: 'We are now working with Prof Davies and the team at [SCTU] to test it in a much larger group of people to see whether it may be a useful early diagnostic tool.'
North Wales Chronicle
31-07-2025
- Health
- North Wales Chronicle
Trial assesses blood test that could detect 10 cancers in earliest stages
The test, known as Enlighten and developed by Proteotype Diagnostics, looks for certain proteins in the blood which indicate that the immune system is responding to the first signs of the disease. It is also being assessed to see if it can identify which type of cancer a patient has. The Modernised trial, led by the Southampton Clinical Trials Unit, is aiming to recruit 1,000 patients, with 450 already taking part. Experts will take samples from people with 10 solid tumour types, including bladder, breast, lung, prostate, ovarian, pancreatic, oesophageal and renal. It will also include patients with colorectal tumours and melanoma, a type of skin cancer. Experts claim Enlighten is different to other blood tests being trialled to detect different cancers. Professor Andy Davies, director of the Southampton Cancer Research UK and National Institute for Health and Care Research Experimental Cancer Medicine Centre, said: 'Most current research into multi-cancer blood tests is focused on detecting abnormal DNA that has been released into the blood stream by cancer cells. 'But this circulating tumour DNA cannot always be detected in the very early stages of cancer. 'We are instead looking at levels of certain proteins found in blood. 'We know that even in the earliest stages of cancer, the body's immune response can lead to higher levels of these proteins being released, and we believe these may be a good way to test for early signs of the disease.' Ian Robinson, 72, from Fawley in Hampshire, was diagnosed with bowel cancer after routine screening and has signed up to take part in the Modernised trial. The grandfather of five said: 'I was sent the NHS bowel cancer screening kit. I think I had done four of these, normally with a negative result, but the most recent one indicated that there was a chance of cancer which was confirmed with a colonoscopy. 'There were no symptoms, no pain, nothing, so you would never know until it was much more advanced and therefore much more difficult to treat. 'Obviously the team here is helping me, so I'm delighted to participate and hopefully help improve the way things are done. 'My mother died from cancer. I now have children and five grandchildren, so yes, research is absolutely vital. The more cancers that can be identified as early as possible, that can benefit future generations, then it's obviously the right way to go.' According to Cancer Research UK, there are around 385,000 new cases of cancer in the UK each year. Dr Victoria Goss, associate professor and head of early diagnosis research at the Southampton Clinical Trials Unit, said: 'When cancers are diagnosed later, there are often fewer treatment options available to patients. 'Detecting cancer early means that treatment can begin sooner, increasing the chances of successful outcomes for patients. 'Improving early diagnosis is therefore a priority for us as researchers and for the NHS. 'But currently there are only four screening programmes in the UK and screening is only for one cancer at a time, so we are aiming to develop simple tests that can potentially pick up the signs of multiple cancers, giving the best possible chance of early, successful treatment.' Dr Emma Yates, co-founder and chief scientific officer of Proteotype Diagnostics, said preliminary studies show Enlighten ' has high levels of accuracy for picking up cancer in its very early stages'. She added: 'We are now working with Professor Davies and the team at the Southampton Clinical Trials Unit to test it in a much larger group of people to see whether it may be a useful early diagnostic tool.' The Modernised trial is funded by the National Institute for Health and Care Research (NIHR) Invention for Innovation programme and the Office for Life Sciences. It is running at five hospital sites in Hampshire and Dorset, and is soon to open in Manchester. Dr Kotryna Temcinaite, head of research communications and engagement at the charity Breast Cancer Now, said: 'Early detection is our best weapon against breast cancer – fundamental to saving more lives from this devastating disease. 'And this exciting early research could have the future potential to help diagnose breast cancer earlier and faster in the future. 'While we wait to see the results from this trial, there are a few simple things people can do to detect breast cancer sooner. This includes regularly checking your breasts and getting any new or unusual changes checked out by a GP and attending breast screening appointments when invited.'
